Physiological distribution and range of normal SUVmax values of 18F-Choline PET/CT

Document Type: Short Communication

Authors

Royal Free Hospital, Pond Street, London, UK

Abstract

Introduction: 18F-Choline PET-CT is an increasingly used technique in patients with prostate cancer. The main indication is to localise the disease in patients with biochemical recurrence. To accurately interpret 18F-Choline PET, knowledge of normal tracer distribution is paramount. The aim of this study was to describe the normal distribution pattern of 18F-Choline by measuring the maximum standardized uptake values (SUVs) of various organs. Methods:18F-Choline PET was performed in ten consecutive patients. Approximately 370 MBq of tracer was injected intravenously and a low amperage CT scan was performed for attenuation correction of PET images.Maximum SUVs were calculated on the reconstructed images for various organs. These SUVmax values depend on multiple factors and could be variable depending on the reconstruction CT methods, acquisition time and region of interest (ROI) parameters. Results:Physiologic symmetric increased tracer uptake was noted in the salivary glands and parotid glands. Intense physiological uptake was present in the liver, pancreas, duodenum, stomach, kidneys and urinary bladder and moderate to intense uptake in the sublingual glands, lacrimal glands, nasal mucosa, thyroid gland, tonsils, adrenal glands, large bowel, bone marrow and spleen. Low-grade-to-moderate uptake was present in the choroid plexus, pituitary gland, soft palate, pharynx, left myocardium, lungs, mediastinal blood pool, testicles and muscles. Prostate and prostatic beds were excluded from the volumes of interest. Conclusion: This study is the first one to describe a normal range of SUVmax values for 18F-CholinePET in various organs.

Keywords

Main Subjects


Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011 Jan;59(1):51-60.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013 Jun;54(6):833-40.

Cimitan M, Evangelista L, Hodolič M, Mariani G, Baseric T, Bodanza V, Saladini G, Volterrani D, Cervino AR, Gregianin M, Puccini G, Guidoccio F, Fettich J, Borsatti E. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med. 2015 Feb;56(2):209-15.

Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol. 1996 Dec;167(6):1503-7.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003 Mar;44(3):331-5.

Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics. 2012;2(3):318-30.

The Royal College of Physicians and the Royal College of Radiologists. Evidence-based indications for the use of PET-CT in UK. Available from: https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-uk-2013.

Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med. 2010 Jun;83(2):53-65.

Beheshti M, Haroon A, Bomanji JB, Langsteger W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin. 2014 Jul;9(3):299-306.

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010 Jan-Feb;12(1):98-107.

García Vicente AM, Núñez García A, Soriano Castrejón AM, Jiménez Londoño GA, Cordero García JM, Palomar Muñoz A. Pitfalls with 18F-choline PET/CT in patients with prostate cancer. Rev Esp Med Nucl Imagen Mol. 2013 Jan;32(1):37-9.

Rietbergen DD, van der Hiel B, Vogel W, Stokkel MP. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT. Nucl Med Commun. 2011 Dec;32(12):1143-7.

Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013 Jun;54(6):833-40.